Aenova is the company formed by the merger of two separate investments made by Bridgepoint: Swiss Caps, Europe’s No 2 contract soft capsule manufacturer of vitamins, minerals, supplements and pharma products, and Dragenopharm, a German contract manufacturer for the generic prescription drugs market.
Founded in 2006, Aenova is one of the leading contract tablet manufacturers in Europe for prescription and OTC drugs and nutritional supplements and is a leading producer of generic drugs. Combining both businesses created the opportunity to improve manufacturing efficiency, and through sharing technological know-how and IP, accelerate both product development and expansion of its customer base.